TORONTO, July 07, 2021 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is pleased to announce it has signed a partnership agreement with Clerkenwell Health (“Clerkenwell”). Clerkenwell is a leading psychedelic Contract Research Organisation (CRO) based in…


Previous articleMYND Life Sciences Provides Corporate Update
Next articleQ & A with Keeno Ahmed-Jones: Dismantling the Echo Chamber of the Psychedelic Renaissance